arrow
T

Tomasz Wróbel

Wroclaw Medical University
H指数:31
被引数:4,659

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival after hematopoietic cell transplantation in children and adults in four decades of experience: nationwide study

四十年经验中儿童和成人造血细胞移植后的生存情况:全国性研究

2026-11-110
OAAI
Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC

维奈克拉为基础疗法对CLL相关自身免疫性血细胞减少症的影响:ERIC开展的一项回顾性研究

2026-11-060
OAAI
Predicted microbiome-associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia

预测的微生物组相关代谢通路与慢性淋巴细胞白血病的免疫检查点调节相关

2026-09-070
OAAI
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study

伊布替尼联合维奈克拉用于复发/难治性套细胞淋巴瘤:SYMPATICO III期研究的最终分析

2026-08-210
OAAI
Laser therapies as the adjunctive treatment of medication-related osteonecrosis of the jaw: Evidence synthesis and clinical recommendations. Official recommendations of the World Federation for Laser Dentistry (WFLD) and the Polish Society for Laser Dentistry (PTSL)

激光疗法作为药物相关颌骨坏死辅助治疗:证据综合与临床建议。世界激光牙科联合会(WFLD)和波兰激光牙科学会(PTSL)的官方建议

2026-01-010
OA
miR-302d-3p expression and genotype are associated with CMV replication after allogeneic haematopoietic stem cell transplantation

miR-302d-3p的表达和基因型与异基因造血干细胞移植后的CMV复制相关

2025-10-080
OAAI
ILT-2 and ILT-4 expression and donor genotype as factors associated with HSCT outcome

ILT-2和ILT-4的表达以及供者基因型作为与HSCT结局相关的因素

2025-10-020
PRE
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study

皮下注射达雷木单抗联合卡非佐米和地塞米松(D-Kd)与卡非佐米和地塞米松(Kd)在既往接受过达雷木单抗治疗的患者中的比较:LYNX研究

2025-10-010
PRE
Soluble MICA concentrations and genetic variability of MICA and its NKG2D receptor as factors affecting Graft-versus-Host Disease development after allogeneic haematopoietic stem cell transplantation

可溶性MICA浓度和MICA及其NKG2D受体的遗传变异性是异基因造血干细胞移植后移植物抗宿主病发展的影响因素

2024-11-010
OAAI